Business
Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll - Phase 1 Trial
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference call scheduled for 4:30 p.m. ET today\n - Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll\n - Phase 1 Trial Evaluating VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021\n - Balance Sheet Remains Strong; Year-End Cash Approximately $250 Million\n\n\nSAN DIEGO, Feb. 17, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2020, and provided an update on its clinical pipeline and other corporate developments.\n\n \n \n \n \n \n \n\n \nHighlights from the Quarter and Year Ended December 31, 2020:\n\"2020 was a strong and productive year for Viking,\" stated Brian Lian, Ph.D., chief executive officer of Viking. \"Despite the challenges posed by the global pandemic, we continued to open clinical sites and proceed with enrollment in our 52-week Phase 2b VOYAGE trial evaluating VK2809 in patients with NASH and fibrosis. Importantly, in the face of a COVID-19 resurgence in recent months, the majority of our U.S. sites remain open, and we continue to add both U.S. and ex-U.S. sites. We currently expect to complete enrollment in the second half of 2021. With respect to our VK0214 program for X-linked adrenoleukodystrophy, we made excellent progress in 2020 and were pleased to announce last fall the initiation of a first-in-human study with this important molecule. Pending successful completion of the Phase 1 single ascending and multiple ascending dose study, we plan to initiate a Phase 1b trial in X-ALD patients. On the personnel side, we recently announced the appointment of Marianne Mancini to the position of COO and Greg Zante to CFO. Both Marianne and Greg have exhibited strong leadership in the management of Viking's clinical operations and financial strategy, respectively, and we are pleased to appoint them to these roles within the organization.\"\nPipeline and Corporate Highlights\nPhase 2b VOYAGE study evaluating VK2809 in biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis continues to enroll; new sites opened in the U.S. and Europe. VK2809 is an orally available small molecule agonist of the thyroid...